Print this page
-
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma.
Protocol: 112105Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Any Site
Lymphoid Leukemia -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors.
Protocol: 112202Applicable Disease Sites: Any Site
-
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Protocol: 112203Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors.
Protocol: 112306Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Brain and Nervous System -
A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors
Protocol: 112307Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy.
Protocol: 112308Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase 1, Multicenter, Open-Label, 2-Stage, Single-Arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-Infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants with Relapsed or Refractory Solid Tumors.
Protocol: 112309Applicable Disease Sites: Any Site
-
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the
Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With
Hematologic Malignancies or Solid Tumors
Protocol: 112401Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Leukemia, other -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx